nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoxetate—ABCC4—Sorafenib—thyroid cancer	0.284	0.364	CbGbCtD
Gadoxetate—ABCC3—Doxorubicin—thyroid cancer	0.226	0.289	CbGbCtD
Gadoxetate—ABCC2—Sorafenib—thyroid cancer	0.169	0.216	CbGbCtD
Gadoxetate—ABCC2—Doxorubicin—thyroid cancer	0.103	0.131	CbGbCtD
Gadoxetate—Cough—Vandetanib—thyroid cancer	0.00117	0.00537	CcSEcCtD
Gadoxetate—Convulsion—Vandetanib—thyroid cancer	0.00116	0.00533	CcSEcCtD
Gadoxetate—Chest pain—Vandetanib—thyroid cancer	0.00114	0.00524	CcSEcCtD
Gadoxetate—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00114	0.00523	CcSEcCtD
Gadoxetate—Renal failure—Sorafenib—thyroid cancer	0.00113	0.00522	CcSEcCtD
Gadoxetate—Anxiety—Vandetanib—thyroid cancer	0.00113	0.00522	CcSEcCtD
Gadoxetate—Myocardial infarction—Sorafenib—thyroid cancer	0.00113	0.0052	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00113	0.0052	CcSEcCtD
Gadoxetate—Dry mouth—Vandetanib—thyroid cancer	0.00111	0.00512	CcSEcCtD
Gadoxetate—Oedema—Vandetanib—thyroid cancer	0.00109	0.00502	CcSEcCtD
Gadoxetate—Parosmia—Doxorubicin—thyroid cancer	0.00109	0.005	CcSEcCtD
Gadoxetate—Infection—Vandetanib—thyroid cancer	0.00108	0.00499	CcSEcCtD
Gadoxetate—Nervous system disorder—Vandetanib—thyroid cancer	0.00107	0.00492	CcSEcCtD
Gadoxetate—Skin disorder—Vandetanib—thyroid cancer	0.00106	0.00488	CcSEcCtD
Gadoxetate—Connective tissue disorder—Sorafenib—thyroid cancer	0.00102	0.00468	CcSEcCtD
Gadoxetate—Paraesthesia—Vandetanib—thyroid cancer	0.00098	0.00451	CcSEcCtD
Gadoxetate—Dyspnoea—Vandetanib—thyroid cancer	0.000973	0.00447	CcSEcCtD
Gadoxetate—Necrosis—Epirubicin—thyroid cancer	0.000971	0.00447	CcSEcCtD
Gadoxetate—Feeling hot—Epirubicin—thyroid cancer	0.000971	0.00447	CcSEcCtD
Gadoxetate—Abscess—Epirubicin—thyroid cancer	0.000963	0.00443	CcSEcCtD
Gadoxetate—Flushing—Sorafenib—thyroid cancer	0.000961	0.00442	CcSEcCtD
Gadoxetate—Cardiac disorder—Sorafenib—thyroid cancer	0.000961	0.00442	CcSEcCtD
Gadoxetate—Decreased appetite—Vandetanib—thyroid cancer	0.000948	0.00436	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000942	0.00433	CcSEcCtD
Gadoxetate—Fatigue—Vandetanib—thyroid cancer	0.000941	0.00433	CcSEcCtD
Gadoxetate—Angiopathy—Sorafenib—thyroid cancer	0.00094	0.00432	CcSEcCtD
Gadoxetate—Immune system disorder—Sorafenib—thyroid cancer	0.000936	0.0043	CcSEcCtD
Gadoxetate—Injection site pain—Epirubicin—thyroid cancer	0.000934	0.0043	CcSEcCtD
Gadoxetate—Mediastinal disorder—Sorafenib—thyroid cancer	0.000933	0.0043	CcSEcCtD
Gadoxetate—Constipation—Vandetanib—thyroid cancer	0.000933	0.00429	CcSEcCtD
Gadoxetate—Arrhythmia—Sorafenib—thyroid cancer	0.000925	0.00426	CcSEcCtD
Gadoxetate—Feeling hot—Doxorubicin—thyroid cancer	0.000899	0.00413	CcSEcCtD
Gadoxetate—Necrosis—Doxorubicin—thyroid cancer	0.000899	0.00413	CcSEcCtD
Gadoxetate—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000892	0.0041	CcSEcCtD
Gadoxetate—Abscess—Doxorubicin—thyroid cancer	0.000891	0.0041	CcSEcCtD
Gadoxetate—Dysgeusia—Sorafenib—thyroid cancer	0.000883	0.00406	CcSEcCtD
Gadoxetate—Extravasation—Epirubicin—thyroid cancer	0.000874	0.00402	CcSEcCtD
Gadoxetate—Injection site pain—Doxorubicin—thyroid cancer	0.000864	0.00397	CcSEcCtD
Gadoxetate—Body temperature increased—Vandetanib—thyroid cancer	0.000862	0.00397	CcSEcCtD
Gadoxetate—Abdominal pain—Vandetanib—thyroid cancer	0.000862	0.00397	CcSEcCtD
Gadoxetate—Cellulitis—Epirubicin—thyroid cancer	0.000838	0.00386	CcSEcCtD
Gadoxetate—Hypocalcaemia—Epirubicin—thyroid cancer	0.000833	0.00383	CcSEcCtD
Gadoxetate—Oliguria—Epirubicin—thyroid cancer	0.000827	0.00381	CcSEcCtD
Gadoxetate—Syncope—Sorafenib—thyroid cancer	0.000809	0.00372	CcSEcCtD
Gadoxetate—Extravasation—Doxorubicin—thyroid cancer	0.000808	0.00372	CcSEcCtD
Gadoxetate—Ulcer—Epirubicin—thyroid cancer	0.000806	0.00371	CcSEcCtD
Gadoxetate—Creatinine increased—Epirubicin—thyroid cancer	0.000801	0.00368	CcSEcCtD
Gadoxetate—Loss of consciousness—Sorafenib—thyroid cancer	0.000792	0.00365	CcSEcCtD
Gadoxetate—Cough—Sorafenib—thyroid cancer	0.000787	0.00362	CcSEcCtD
Gadoxetate—Asthenia—Vandetanib—thyroid cancer	0.000783	0.0036	CcSEcCtD
Gadoxetate—Cellulitis—Doxorubicin—thyroid cancer	0.000776	0.00357	CcSEcCtD
Gadoxetate—Pruritus—Vandetanib—thyroid cancer	0.000772	0.00355	CcSEcCtD
Gadoxetate—Hypocalcaemia—Doxorubicin—thyroid cancer	0.00077	0.00354	CcSEcCtD
Gadoxetate—Oliguria—Doxorubicin—thyroid cancer	0.000765	0.00352	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000762	0.00351	CcSEcCtD
Gadoxetate—Injection site reaction—Epirubicin—thyroid cancer	0.000758	0.00349	CcSEcCtD
Gadoxetate—Dry mouth—Sorafenib—thyroid cancer	0.000751	0.00345	CcSEcCtD
Gadoxetate—Diarrhoea—Vandetanib—thyroid cancer	0.000746	0.00343	CcSEcCtD
Gadoxetate—Ulcer—Doxorubicin—thyroid cancer	0.000746	0.00343	CcSEcCtD
Gadoxetate—Creatinine increased—Doxorubicin—thyroid cancer	0.000741	0.00341	CcSEcCtD
Gadoxetate—Salivary hypersecretion—Epirubicin—thyroid cancer	0.00074	0.00341	CcSEcCtD
Gadoxetate—Anaphylactic shock—Sorafenib—thyroid cancer	0.000736	0.00339	CcSEcCtD
Gadoxetate—Infection—Sorafenib—thyroid cancer	0.000731	0.00336	CcSEcCtD
Gadoxetate—Shock—Sorafenib—thyroid cancer	0.000724	0.00333	CcSEcCtD
Gadoxetate—Fluid retention—Epirubicin—thyroid cancer	0.000724	0.00333	CcSEcCtD
Gadoxetate—Nervous system disorder—Sorafenib—thyroid cancer	0.000722	0.00332	CcSEcCtD
Gadoxetate—Dizziness—Vandetanib—thyroid cancer	0.000721	0.00332	CcSEcCtD
Gadoxetate—Blood urea increased—Epirubicin—thyroid cancer	0.00072	0.00331	CcSEcCtD
Gadoxetate—Skin disorder—Sorafenib—thyroid cancer	0.000715	0.00329	CcSEcCtD
Gadoxetate—Anorexia—Sorafenib—thyroid cancer	0.000701	0.00323	CcSEcCtD
Gadoxetate—Injection site reaction—Doxorubicin—thyroid cancer	0.000701	0.00323	CcSEcCtD
Gadoxetate—Vomiting—Vandetanib—thyroid cancer	0.000694	0.00319	CcSEcCtD
Gadoxetate—Rash maculo-papular—Epirubicin—thyroid cancer	0.000693	0.00319	CcSEcCtD
Gadoxetate—Rash—Vandetanib—thyroid cancer	0.000688	0.00316	CcSEcCtD
Gadoxetate—Dermatitis—Vandetanib—thyroid cancer	0.000687	0.00316	CcSEcCtD
Gadoxetate—Salivary hypersecretion—Doxorubicin—thyroid cancer	0.000685	0.00315	CcSEcCtD
Gadoxetate—Headache—Vandetanib—thyroid cancer	0.000683	0.00314	CcSEcCtD
Gadoxetate—Fluid retention—Doxorubicin—thyroid cancer	0.00067	0.00308	CcSEcCtD
Gadoxetate—Blood urea increased—Doxorubicin—thyroid cancer	0.000666	0.00306	CcSEcCtD
Gadoxetate—Sepsis—Epirubicin—thyroid cancer	0.000661	0.00304	CcSEcCtD
Gadoxetate—Dyspnoea—Sorafenib—thyroid cancer	0.000656	0.00302	CcSEcCtD
Gadoxetate—Nausea—Vandetanib—thyroid cancer	0.000648	0.00298	CcSEcCtD
Gadoxetate—Phlebitis—Epirubicin—thyroid cancer	0.000642	0.00296	CcSEcCtD
Gadoxetate—Rash maculo-papular—Doxorubicin—thyroid cancer	0.000641	0.00295	CcSEcCtD
Gadoxetate—Decreased appetite—Sorafenib—thyroid cancer	0.00064	0.00294	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000635	0.00292	CcSEcCtD
Gadoxetate—Fatigue—Sorafenib—thyroid cancer	0.000634	0.00292	CcSEcCtD
Gadoxetate—Constipation—Sorafenib—thyroid cancer	0.000629	0.0029	CcSEcCtD
Gadoxetate—Sepsis—Doxorubicin—thyroid cancer	0.000612	0.00282	CcSEcCtD
Gadoxetate—Cardiac failure congestive—Epirubicin—thyroid cancer	0.00061	0.00281	CcSEcCtD
Gadoxetate—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000602	0.00277	CcSEcCtD
Gadoxetate—Renal failure acute—Epirubicin—thyroid cancer	0.000599	0.00276	CcSEcCtD
Gadoxetate—Phlebitis—Doxorubicin—thyroid cancer	0.000594	0.00273	CcSEcCtD
Gadoxetate—Urticaria—Sorafenib—thyroid cancer	0.000585	0.00269	CcSEcCtD
Gadoxetate—Abdominal pain—Sorafenib—thyroid cancer	0.000582	0.00268	CcSEcCtD
Gadoxetate—Body temperature increased—Sorafenib—thyroid cancer	0.000582	0.00268	CcSEcCtD
Gadoxetate—Renal impairment—Epirubicin—thyroid cancer	0.000581	0.00268	CcSEcCtD
Gadoxetate—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000572	0.00263	CcSEcCtD
Gadoxetate—Cerebrovascular accident—Epirubicin—thyroid cancer	0.000565	0.0026	CcSEcCtD
Gadoxetate—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000565	0.0026	CcSEcCtD
Gadoxetate—Renal failure acute—Doxorubicin—thyroid cancer	0.000555	0.00255	CcSEcCtD
Gadoxetate—Hypersensitivity—Sorafenib—thyroid cancer	0.000542	0.00249	CcSEcCtD
Gadoxetate—Renal impairment—Doxorubicin—thyroid cancer	0.000538	0.00248	CcSEcCtD
Gadoxetate—Face oedema—Epirubicin—thyroid cancer	0.000534	0.00246	CcSEcCtD
Gadoxetate—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000529	0.00243	CcSEcCtD
Gadoxetate—Asthenia—Sorafenib—thyroid cancer	0.000528	0.00243	CcSEcCtD
Gadoxetate—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.000522	0.0024	CcSEcCtD
Gadoxetate—Pruritus—Sorafenib—thyroid cancer	0.000521	0.0024	CcSEcCtD
Gadoxetate—Blood creatinine increased—Epirubicin—thyroid cancer	0.000518	0.00239	CcSEcCtD
Gadoxetate—Dehydration—Epirubicin—thyroid cancer	0.000515	0.00237	CcSEcCtD
Gadoxetate—Hypokalaemia—Epirubicin—thyroid cancer	0.000504	0.00232	CcSEcCtD
Gadoxetate—Diarrhoea—Sorafenib—thyroid cancer	0.000503	0.00232	CcSEcCtD
Gadoxetate—Face oedema—Doxorubicin—thyroid cancer	0.000494	0.00227	CcSEcCtD
Gadoxetate—Dizziness—Sorafenib—thyroid cancer	0.000487	0.00224	CcSEcCtD
Gadoxetate—Abdominal distension—Epirubicin—thyroid cancer	0.000481	0.00222	CcSEcCtD
Gadoxetate—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00048	0.00221	CcSEcCtD
Gadoxetate—Dysphagia—Epirubicin—thyroid cancer	0.000478	0.0022	CcSEcCtD
Gadoxetate—Dehydration—Doxorubicin—thyroid cancer	0.000476	0.00219	CcSEcCtD
Gadoxetate—Vomiting—Sorafenib—thyroid cancer	0.000468	0.00215	CcSEcCtD
Gadoxetate—Hypokalaemia—Doxorubicin—thyroid cancer	0.000466	0.00214	CcSEcCtD
Gadoxetate—Rash—Sorafenib—thyroid cancer	0.000464	0.00213	CcSEcCtD
Gadoxetate—Dermatitis—Sorafenib—thyroid cancer	0.000464	0.00213	CcSEcCtD
Gadoxetate—Headache—Sorafenib—thyroid cancer	0.000461	0.00212	CcSEcCtD
Gadoxetate—Bronchitis—Epirubicin—thyroid cancer	0.00046	0.00212	CcSEcCtD
Gadoxetate—Abdominal distension—Doxorubicin—thyroid cancer	0.000445	0.00205	CcSEcCtD
Gadoxetate—Dysphagia—Doxorubicin—thyroid cancer	0.000443	0.00204	CcSEcCtD
Gadoxetate—Nausea—Sorafenib—thyroid cancer	0.000437	0.00201	CcSEcCtD
Gadoxetate—Bronchitis—Doxorubicin—thyroid cancer	0.000426	0.00196	CcSEcCtD
Gadoxetate—Renal failure—Epirubicin—thyroid cancer	0.000419	0.00193	CcSEcCtD
Gadoxetate—Conjunctivitis—Epirubicin—thyroid cancer	0.000414	0.00191	CcSEcCtD
Gadoxetate—Renal failure—Doxorubicin—thyroid cancer	0.000388	0.00178	CcSEcCtD
Gadoxetate—Rhinitis—Epirubicin—thyroid cancer	0.000384	0.00177	CcSEcCtD
Gadoxetate—Conjunctivitis—Doxorubicin—thyroid cancer	0.000384	0.00176	CcSEcCtD
Gadoxetate—Hypoaesthesia—Epirubicin—thyroid cancer	0.000381	0.00175	CcSEcCtD
Gadoxetate—Connective tissue disorder—Epirubicin—thyroid cancer	0.000376	0.00173	CcSEcCtD
Gadoxetate—Flushing—Epirubicin—thyroid cancer	0.000355	0.00163	CcSEcCtD
Gadoxetate—Cardiac disorder—Epirubicin—thyroid cancer	0.000355	0.00163	CcSEcCtD
Gadoxetate—Rhinitis—Doxorubicin—thyroid cancer	0.000355	0.00163	CcSEcCtD
Gadoxetate—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000352	0.00162	CcSEcCtD
Gadoxetate—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000348	0.0016	CcSEcCtD
Gadoxetate—Angiopathy—Epirubicin—thyroid cancer	0.000347	0.0016	CcSEcCtD
Gadoxetate—Immune system disorder—Epirubicin—thyroid cancer	0.000346	0.00159	CcSEcCtD
Gadoxetate—Mediastinal disorder—Epirubicin—thyroid cancer	0.000345	0.00159	CcSEcCtD
Gadoxetate—Chills—Epirubicin—thyroid cancer	0.000343	0.00158	CcSEcCtD
Gadoxetate—Arrhythmia—Epirubicin—thyroid cancer	0.000342	0.00157	CcSEcCtD
Gadoxetate—Flushing—Doxorubicin—thyroid cancer	0.000329	0.00151	CcSEcCtD
Gadoxetate—Cardiac disorder—Doxorubicin—thyroid cancer	0.000329	0.00151	CcSEcCtD
Gadoxetate—Flatulence—Epirubicin—thyroid cancer	0.000328	0.00151	CcSEcCtD
Gadoxetate—Dysgeusia—Epirubicin—thyroid cancer	0.000326	0.0015	CcSEcCtD
Gadoxetate—Back pain—Epirubicin—thyroid cancer	0.000322	0.00148	CcSEcCtD
Gadoxetate—Angiopathy—Doxorubicin—thyroid cancer	0.000321	0.00148	CcSEcCtD
Gadoxetate—Immune system disorder—Doxorubicin—thyroid cancer	0.00032	0.00147	CcSEcCtD
Gadoxetate—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000319	0.00147	CcSEcCtD
Gadoxetate—Chills—Doxorubicin—thyroid cancer	0.000318	0.00146	CcSEcCtD
Gadoxetate—Arrhythmia—Doxorubicin—thyroid cancer	0.000316	0.00146	CcSEcCtD
Gadoxetate—Vision blurred—Epirubicin—thyroid cancer	0.000314	0.00144	CcSEcCtD
Gadoxetate—Ill-defined disorder—Epirubicin—thyroid cancer	0.000309	0.00142	CcSEcCtD
Gadoxetate—Agitation—Epirubicin—thyroid cancer	0.000306	0.00141	CcSEcCtD
Gadoxetate—Flatulence—Doxorubicin—thyroid cancer	0.000304	0.0014	CcSEcCtD
Gadoxetate—Dysgeusia—Doxorubicin—thyroid cancer	0.000302	0.00139	CcSEcCtD
Gadoxetate—Malaise—Epirubicin—thyroid cancer	0.000301	0.00138	CcSEcCtD
Gadoxetate—Vertigo—Epirubicin—thyroid cancer	0.000299	0.00138	CcSEcCtD
Gadoxetate—Syncope—Epirubicin—thyroid cancer	0.000299	0.00137	CcSEcCtD
Gadoxetate—Back pain—Doxorubicin—thyroid cancer	0.000298	0.00137	CcSEcCtD
Gadoxetate—Palpitations—Epirubicin—thyroid cancer	0.000294	0.00135	CcSEcCtD
Gadoxetate—Loss of consciousness—Epirubicin—thyroid cancer	0.000293	0.00135	CcSEcCtD
Gadoxetate—Cough—Epirubicin—thyroid cancer	0.000291	0.00134	CcSEcCtD
Gadoxetate—Vision blurred—Doxorubicin—thyroid cancer	0.000291	0.00134	CcSEcCtD
Gadoxetate—Convulsion—Epirubicin—thyroid cancer	0.000289	0.00133	CcSEcCtD
Gadoxetate—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000286	0.00132	CcSEcCtD
Gadoxetate—Chest pain—Epirubicin—thyroid cancer	0.000284	0.00131	CcSEcCtD
Gadoxetate—Agitation—Doxorubicin—thyroid cancer	0.000283	0.0013	CcSEcCtD
Gadoxetate—Anxiety—Epirubicin—thyroid cancer	0.000283	0.0013	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000282	0.0013	CcSEcCtD
Gadoxetate—Discomfort—Epirubicin—thyroid cancer	0.00028	0.00129	CcSEcCtD
Gadoxetate—Malaise—Doxorubicin—thyroid cancer	0.000278	0.00128	CcSEcCtD
Gadoxetate—Dry mouth—Epirubicin—thyroid cancer	0.000277	0.00128	CcSEcCtD
Gadoxetate—Vertigo—Doxorubicin—thyroid cancer	0.000277	0.00127	CcSEcCtD
Gadoxetate—Syncope—Doxorubicin—thyroid cancer	0.000277	0.00127	CcSEcCtD
Gadoxetate—Palpitations—Doxorubicin—thyroid cancer	0.000272	0.00125	CcSEcCtD
Gadoxetate—Oedema—Epirubicin—thyroid cancer	0.000272	0.00125	CcSEcCtD
Gadoxetate—Anaphylactic shock—Epirubicin—thyroid cancer	0.000272	0.00125	CcSEcCtD
Gadoxetate—Loss of consciousness—Doxorubicin—thyroid cancer	0.000271	0.00125	CcSEcCtD
Gadoxetate—Infection—Epirubicin—thyroid cancer	0.00027	0.00124	CcSEcCtD
Gadoxetate—Cough—Doxorubicin—thyroid cancer	0.000269	0.00124	CcSEcCtD
Gadoxetate—Shock—Epirubicin—thyroid cancer	0.000268	0.00123	CcSEcCtD
Gadoxetate—Convulsion—Doxorubicin—thyroid cancer	0.000267	0.00123	CcSEcCtD
Gadoxetate—Nervous system disorder—Epirubicin—thyroid cancer	0.000267	0.00123	CcSEcCtD
Gadoxetate—Tachycardia—Epirubicin—thyroid cancer	0.000265	0.00122	CcSEcCtD
Gadoxetate—Skin disorder—Epirubicin—thyroid cancer	0.000264	0.00122	CcSEcCtD
Gadoxetate—Hyperhidrosis—Epirubicin—thyroid cancer	0.000263	0.00121	CcSEcCtD
Gadoxetate—Chest pain—Doxorubicin—thyroid cancer	0.000262	0.00121	CcSEcCtD
Gadoxetate—Anxiety—Doxorubicin—thyroid cancer	0.000262	0.0012	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000261	0.0012	CcSEcCtD
Gadoxetate—Discomfort—Doxorubicin—thyroid cancer	0.000259	0.00119	CcSEcCtD
Gadoxetate—Anorexia—Epirubicin—thyroid cancer	0.000259	0.00119	CcSEcCtD
Gadoxetate—Dry mouth—Doxorubicin—thyroid cancer	0.000257	0.00118	CcSEcCtD
Gadoxetate—Hypotension—Epirubicin—thyroid cancer	0.000254	0.00117	CcSEcCtD
Gadoxetate—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000252	0.00116	CcSEcCtD
Gadoxetate—Oedema—Doxorubicin—thyroid cancer	0.000252	0.00116	CcSEcCtD
Gadoxetate—Infection—Doxorubicin—thyroid cancer	0.00025	0.00115	CcSEcCtD
Gadoxetate—Shock—Doxorubicin—thyroid cancer	0.000248	0.00114	CcSEcCtD
Gadoxetate—Nervous system disorder—Doxorubicin—thyroid cancer	0.000247	0.00114	CcSEcCtD
Gadoxetate—Tachycardia—Doxorubicin—thyroid cancer	0.000246	0.00113	CcSEcCtD
Gadoxetate—Skin disorder—Doxorubicin—thyroid cancer	0.000244	0.00112	CcSEcCtD
Gadoxetate—Paraesthesia—Epirubicin—thyroid cancer	0.000244	0.00112	CcSEcCtD
Gadoxetate—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000243	0.00112	CcSEcCtD
Gadoxetate—Dyspnoea—Epirubicin—thyroid cancer	0.000242	0.00112	CcSEcCtD
Gadoxetate—Anorexia—Doxorubicin—thyroid cancer	0.00024	0.0011	CcSEcCtD
Gadoxetate—Decreased appetite—Epirubicin—thyroid cancer	0.000236	0.00109	CcSEcCtD
Gadoxetate—Hypotension—Doxorubicin—thyroid cancer	0.000235	0.00108	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000235	0.00108	CcSEcCtD
Gadoxetate—Fatigue—Epirubicin—thyroid cancer	0.000234	0.00108	CcSEcCtD
Gadoxetate—Constipation—Epirubicin—thyroid cancer	0.000233	0.00107	CcSEcCtD
Gadoxetate—Paraesthesia—Doxorubicin—thyroid cancer	0.000226	0.00104	CcSEcCtD
Gadoxetate—Dyspnoea—Doxorubicin—thyroid cancer	0.000224	0.00103	CcSEcCtD
Gadoxetate—Feeling abnormal—Epirubicin—thyroid cancer	0.000224	0.00103	CcSEcCtD
Gadoxetate—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000222	0.00102	CcSEcCtD
Gadoxetate—Decreased appetite—Doxorubicin—thyroid cancer	0.000219	0.00101	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000217	0.001	CcSEcCtD
Gadoxetate—Fatigue—Doxorubicin—thyroid cancer	0.000217	0.000998	CcSEcCtD
Gadoxetate—Urticaria—Epirubicin—thyroid cancer	0.000216	0.000994	CcSEcCtD
Gadoxetate—Constipation—Doxorubicin—thyroid cancer	0.000215	0.00099	CcSEcCtD
Gadoxetate—Body temperature increased—Epirubicin—thyroid cancer	0.000215	0.000989	CcSEcCtD
Gadoxetate—Abdominal pain—Epirubicin—thyroid cancer	0.000215	0.000989	CcSEcCtD
Gadoxetate—Feeling abnormal—Doxorubicin—thyroid cancer	0.000207	0.000954	CcSEcCtD
Gadoxetate—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000206	0.000947	CcSEcCtD
Gadoxetate—Hypersensitivity—Epirubicin—thyroid cancer	0.0002	0.000922	CcSEcCtD
Gadoxetate—Urticaria—Doxorubicin—thyroid cancer	0.0002	0.00092	CcSEcCtD
Gadoxetate—Abdominal pain—Doxorubicin—thyroid cancer	0.000199	0.000915	CcSEcCtD
Gadoxetate—Body temperature increased—Doxorubicin—thyroid cancer	0.000199	0.000915	CcSEcCtD
Gadoxetate—Asthenia—Epirubicin—thyroid cancer	0.000195	0.000898	CcSEcCtD
Gadoxetate—Pruritus—Epirubicin—thyroid cancer	0.000192	0.000885	CcSEcCtD
Gadoxetate—Diarrhoea—Epirubicin—thyroid cancer	0.000186	0.000856	CcSEcCtD
Gadoxetate—Hypersensitivity—Doxorubicin—thyroid cancer	0.000185	0.000853	CcSEcCtD
Gadoxetate—Asthenia—Doxorubicin—thyroid cancer	0.000181	0.000831	CcSEcCtD
Gadoxetate—Dizziness—Epirubicin—thyroid cancer	0.00018	0.000827	CcSEcCtD
Gadoxetate—Pruritus—Doxorubicin—thyroid cancer	0.000178	0.000819	CcSEcCtD
Gadoxetate—Vomiting—Epirubicin—thyroid cancer	0.000173	0.000796	CcSEcCtD
Gadoxetate—Diarrhoea—Doxorubicin—thyroid cancer	0.000172	0.000792	CcSEcCtD
Gadoxetate—Rash—Epirubicin—thyroid cancer	0.000171	0.000789	CcSEcCtD
Gadoxetate—Dermatitis—Epirubicin—thyroid cancer	0.000171	0.000788	CcSEcCtD
Gadoxetate—Headache—Epirubicin—thyroid cancer	0.00017	0.000784	CcSEcCtD
Gadoxetate—Dizziness—Doxorubicin—thyroid cancer	0.000166	0.000766	CcSEcCtD
Gadoxetate—Nausea—Epirubicin—thyroid cancer	0.000162	0.000743	CcSEcCtD
Gadoxetate—Vomiting—Doxorubicin—thyroid cancer	0.00016	0.000736	CcSEcCtD
Gadoxetate—Rash—Doxorubicin—thyroid cancer	0.000159	0.00073	CcSEcCtD
Gadoxetate—Dermatitis—Doxorubicin—thyroid cancer	0.000159	0.000729	CcSEcCtD
Gadoxetate—Headache—Doxorubicin—thyroid cancer	0.000158	0.000725	CcSEcCtD
Gadoxetate—Nausea—Doxorubicin—thyroid cancer	0.000149	0.000688	CcSEcCtD
Gadoxetate—SLCO1B3—Recycling of bile acids and salts—RXRA—thyroid cancer	0.00012	0.0731	CbGpPWpGaD
Gadoxetate—ABCC3—Recycling of bile acids and salts—RXRA—thyroid cancer	0.000109	0.0659	CbGpPWpGaD
Gadoxetate—SLCO1B1—Recycling of bile acids and salts—RXRA—thyroid cancer	8.09e-05	0.0491	CbGpPWpGaD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—SMUG1—thyroid cancer	6.77e-05	0.0411	CbGpPWpGaD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—SMUG1—thyroid cancer	6.37e-05	0.0387	CbGpPWpGaD
Gadoxetate—SLCO1B3—Bile acid and bile salt metabolism—RXRA—thyroid cancer	6.29e-05	0.0382	CbGpPWpGaD
Gadoxetate—ABCC3—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	6.24e-05	0.0379	CbGpPWpGaD
Gadoxetate—ABCC4—Ectoderm Differentiation—TRIM33—thyroid cancer	5.93e-05	0.036	CbGpPWpGaD
Gadoxetate—ABCC3—Bile acid and bile salt metabolism—RXRA—thyroid cancer	5.68e-05	0.0345	CbGpPWpGaD
Gadoxetate—ABCC2—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	4.94e-05	0.03	CbGpPWpGaD
Gadoxetate—SLCO1B1—Bile acid and bile salt metabolism—RXRA—thyroid cancer	4.23e-05	0.0257	CbGpPWpGaD
Gadoxetate—ABCC4—Ectoderm Differentiation—TCF7L1—thyroid cancer	3.96e-05	0.024	CbGpPWpGaD
Gadoxetate—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	3.75e-05	0.0228	CbGpPWpGaD
Gadoxetate—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	2.97e-05	0.0181	CbGpPWpGaD
Gadoxetate—ABCC3—NRF2 pathway—SLC5A5—thyroid cancer	2.2e-05	0.0134	CbGpPWpGaD
Gadoxetate—ABCC4—NRF2 pathway—SLC5A5—thyroid cancer	2.07e-05	0.0126	CbGpPWpGaD
Gadoxetate—SLCO1B3—SLC-mediated transmembrane transport—TPR—thyroid cancer	2.06e-05	0.0125	CbGpPWpGaD
Gadoxetate—SLCO1B3—SLC-mediated transmembrane transport—CP—thyroid cancer	2.06e-05	0.0125	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	1.91e-05	0.0116	CbGpPWpGaD
Gadoxetate—ABCC3—NRF2 pathway—RXRA—thyroid cancer	1.85e-05	0.0112	CbGpPWpGaD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—TP53—thyroid cancer	1.8e-05	0.0109	CbGpPWpGaD
Gadoxetate—ABCC2—NRF2 pathway—SLC5A5—thyroid cancer	1.75e-05	0.0106	CbGpPWpGaD
Gadoxetate—ABCC4—NRF2 pathway—RXRA—thyroid cancer	1.74e-05	0.0106	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	1.73e-05	0.0105	CbGpPWpGaD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—TP53—thyroid cancer	1.69e-05	0.0103	CbGpPWpGaD
Gadoxetate—ABCC3—NRF2 pathway—NRG1—thyroid cancer	1.6e-05	0.00972	CbGpPWpGaD
Gadoxetate—SLCO1B3—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	1.54e-05	0.00935	CbGpPWpGaD
Gadoxetate—ABCC4—NRF2 pathway—NRG1—thyroid cancer	1.51e-05	0.00914	CbGpPWpGaD
Gadoxetate—ABCC2—NRF2 pathway—RXRA—thyroid cancer	1.47e-05	0.00891	CbGpPWpGaD
Gadoxetate—SLCO1B1—SLC-mediated transmembrane transport—TPR—thyroid cancer	1.38e-05	0.00839	CbGpPWpGaD
Gadoxetate—SLCO1B1—SLC-mediated transmembrane transport—CP—thyroid cancer	1.38e-05	0.00839	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—MINPP1—thyroid cancer	1.32e-05	0.00803	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	1.29e-05	0.00781	CbGpPWpGaD
Gadoxetate—ABCC2—NRF2 pathway—NRG1—thyroid cancer	1.27e-05	0.00771	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—MINPP1—thyroid cancer	1.19e-05	0.00725	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—NDUFA13—thyroid cancer	1.12e-05	0.00683	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CHST14—thyroid cancer	1.06e-05	0.00642	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—TPR—thyroid cancer	1.04e-05	0.00635	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—CP—thyroid cancer	1.04e-05	0.00635	CbGpPWpGaD
Gadoxetate—SLCO1B1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	1.03e-05	0.00628	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.03e-05	0.00624	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—NDUFA13—thyroid cancer	1.01e-05	0.00616	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—PRKAR1A—thyroid cancer	1.01e-05	0.00612	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CHST14—thyroid cancer	9.54e-06	0.00579	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—CP—thyroid cancer	9.43e-06	0.00573	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—TPR—thyroid cancer	9.43e-06	0.00573	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	9.28e-06	0.00563	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—MINPP1—thyroid cancer	8.89e-06	0.0054	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—TPR—thyroid cancer	8.86e-06	0.00538	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—CP—thyroid cancer	8.86e-06	0.00538	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	8.72e-06	0.0053	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—HPGD—thyroid cancer	8.52e-06	0.00517	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.82e-06	0.00475	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—HPGD—thyroid cancer	7.69e-06	0.00467	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—NDUFA13—thyroid cancer	7.55e-06	0.00459	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—CP—thyroid cancer	7.48e-06	0.00454	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—TPR—thyroid cancer	7.48e-06	0.00454	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	7.35e-06	0.00447	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CHST14—thyroid cancer	7.1e-06	0.00431	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	7.06e-06	0.00429	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—TPR—thyroid cancer	7.02e-06	0.00426	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—CP—thyroid cancer	7.02e-06	0.00426	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.91e-06	0.0042	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	6.91e-06	0.00419	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—IFNA2—thyroid cancer	6.67e-06	0.00405	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	6.64e-06	0.00403	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—RXRA—thyroid cancer	6.57e-06	0.00399	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.24e-06	0.00379	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.93e-06	0.0036	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—HPGD—thyroid cancer	5.73e-06	0.00348	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.6e-06	0.0034	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—RXRA—thyroid cancer	5.58e-06	0.00339	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	5.26e-06	0.00319	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—TPR—thyroid cancer	4.89e-06	0.00297	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PRKAR1A—thyroid cancer	4.82e-06	0.00292	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.7e-06	0.00285	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.64e-06	0.00282	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—TPR—thyroid cancer	4.42e-06	0.00268	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—RXRA—thyroid cancer	4.42e-06	0.00268	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.36e-06	0.00265	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PRKAR1A—thyroid cancer	4.34e-06	0.00264	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.94e-06	0.00239	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—SLC5A5—thyroid cancer	3.66e-06	0.00222	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.43e-06	0.00208	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—SLC5A5—thyroid cancer	3.31e-06	0.00201	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—TPR—thyroid cancer	3.29e-06	0.002	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PRKAR1A—thyroid cancer	3.24e-06	0.00196	CbGpPWpGaD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	3.12e-06	0.00189	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	3.1e-06	0.00188	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—RXRA—thyroid cancer	3.08e-06	0.00187	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.99e-06	0.00182	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.93e-06	0.00178	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—RXRA—thyroid cancer	2.78e-06	0.00169	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.7e-06	0.00164	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—NRAS—thyroid cancer	2.49e-06	0.00151	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—SLC5A5—thyroid cancer	2.46e-06	0.00149	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.31e-06	0.0014	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—KRAS—thyroid cancer	2.14e-06	0.0013	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—RXRA—thyroid cancer	2.07e-06	0.00126	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.01e-06	0.00122	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PPARG—thyroid cancer	1.94e-06	0.00118	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—TP53—thyroid cancer	1.9e-06	0.00116	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—HRAS—thyroid cancer	1.82e-06	0.00111	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PPARG—thyroid cancer	1.75e-06	0.00106	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—AKT1—thyroid cancer	1.61e-06	0.000976	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PTGS2—thyroid cancer	1.53e-06	0.000928	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PTGS2—thyroid cancer	1.38e-06	0.000838	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PTEN—thyroid cancer	1.33e-06	0.00081	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PPARG—thyroid cancer	1.31e-06	0.000793	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PTEN—thyroid cancer	1.2e-06	0.000731	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PTGS2—thyroid cancer	1.03e-06	0.000624	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PTEN—thyroid cancer	8.96e-07	0.000544	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—AKT1—thyroid cancer	7.68e-07	0.000467	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—AKT1—thyroid cancer	6.93e-07	0.000421	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—AKT1—thyroid cancer	5.16e-07	0.000314	CbGpPWpGaD
